Though Mineralocorticoid receptors antagonist (MRAs)are in the markets since long ,such as spironolactone which is one of the basic and most proven MRA and also Eplerenone both known for there beneficial effects on congestive cardiac failures and chronic kidney diseases. There was not much enough evidence of its use in diabetic kidney diseases and in cardiac complications in patients with Diabetes mellitus. Recent introduction of Finerenone a novel MRA for the betterment in cardiac and kidney complications is being studied and was found to be potential game changer for Diabetic patients with reduced eGfR and Hfref. This review will make physicians analyse the efficacy of the recent MRA, Finerenone on cardiac and renal profiles of the Diabetic patients and will also guide on the current status of the drug.